Beta Bionics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	69.83	65.12	12	0.18
Revenue Growth (YoY)	38911.17%	442.93%	6601.12%	-
Cost of Revenue	32.17	29.24	5.69	-
Gross Profit	37.66	35.89	6.31	0.18
Selling, General & Admin	63.8	54.96	24.22	33.5
Research & Development	28.3	26.18	17.94	31.43
Operating Expenses	92.1	81.14	42.16	64.92
Operating Income	-54.44	-45.25	-35.85	-64.74
Interest Expense	-	-	-	-0.01
Interest & Investment Income	5.21	3.91	1.78	0.2
Other Non Operating Income (Expenses)	-21.73	-13.41	-10.03	0.91
EBT Excluding Unusual Items	-70.96	-54.76	-44.1	-63.65
Other Unusual Items	-	-	-	-1.1
Pretax Income	-70.96	-54.76	-44.1	-64.75
Net Income	-70.96	-54.76	-44.1	-64.75
Net Income to Common	-70.96	-54.76	-44.1	-64.75
Shares Outstanding (Basic)	13	6	5	5
Shares Outstanding (Diluted)	13	6	5	5
Shares Change (YoY)	150.89%	20.01%	6.13%	-
EPS (Basic)	-5.66	-8.60	-8.31	-12.96
EPS (Diluted)	-5.66	-8.60	-8.31	-12.96
Free Cash Flow	-59.43	-51.67	-32.85	-60.98
Free Cash Flow Per Share	-4.74	-8.12	-6.19	-12.20
Gross Margin	53.93%	55.11%	52.59%	100.00%
Operating Margin	-77.96%	-69.48%	-298.88%	-36169.83%
Profit Margin	-101.62%	-84.08%	-367.64%	-36173.74%
Free Cash Flow Margin	-85.10%	-79.34%	-273.84%	-34067.04%
EBITDA	-53.27	-44.1	-34.62	-63.4
EBITDA Margin	-76.29%	-67.72%	-288.65%	-
D&A For EBITDA	1.17	1.15	1.23	1.35
EBIT	-54.44	-45.25	-35.85	-64.74
EBIT Margin	-77.96%	-69.48%	-298.87%	-
Revenue as Reported	-	-	-	0.18

Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q